MX9700081A - Composiciones farmaceuticas de tacrina. - Google Patents

Composiciones farmaceuticas de tacrina.

Info

Publication number
MX9700081A
MX9700081A MX9700081A MX9700081A MX9700081A MX 9700081 A MX9700081 A MX 9700081A MX 9700081 A MX9700081 A MX 9700081A MX 9700081 A MX9700081 A MX 9700081A MX 9700081 A MX9700081 A MX 9700081A
Authority
MX
Mexico
Prior art keywords
tacrine
pharmaceutical compositions
administering
patient
disclosed
Prior art date
Application number
MX9700081A
Other languages
English (en)
Inventor
George V Guittard
Jerry D Childers
Patrick S L Wong
Fernando E Gumucio
David J Kidney
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of MX9700081A publication Critical patent/MX9700081A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se describe una forma de dosis para administracion de 10 mg a 1200 mg de tacrina a un paciente en necesidad de terapia de tacrina.
MX9700081A 1994-06-27 1995-06-14 Composiciones farmaceuticas de tacrina. MX9700081A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/266,045 US5698224A (en) 1994-06-27 1994-06-27 Tacrine therapy
PCT/US1995/007726 WO1996000065A1 (en) 1994-06-27 1995-06-14 Tacrine pharmaceutical compositions

Publications (1)

Publication Number Publication Date
MX9700081A true MX9700081A (es) 1997-04-30

Family

ID=23012934

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9700081A MX9700081A (es) 1994-06-27 1995-06-14 Composiciones farmaceuticas de tacrina.

Country Status (11)

Country Link
US (2) US5698224A (es)
EP (1) EP0768880A1 (es)
JP (1) JPH10507440A (es)
KR (1) KR970703768A (es)
AU (1) AU685297B2 (es)
CA (1) CA2187332A1 (es)
FI (1) FI965202A (es)
MX (1) MX9700081A (es)
NO (1) NO965539L (es)
NZ (1) NZ288951A (es)
WO (1) WO1996000065A1 (es)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7049078B2 (en) 1994-04-27 2006-05-23 Judés Poirier Apolipoprotein E polymorphism and treatment of alzheimer's disease
GB9408465D0 (en) * 1994-04-27 1994-06-22 Univ Mcgill Apolipoprotein e polymorphism & treatment of alzheimer's disease
US5698224A (en) * 1994-06-27 1997-12-16 Alza Corporation Tacrine therapy
US5593769A (en) * 1995-06-14 1997-01-14 Minnesota Mining And Manufacturing Company Polyurethane pad covering for gel filled articles
AU721653B2 (en) * 1996-10-25 2000-07-13 Supernus Pharmaceuticals, Inc. Soluble form osmotic dose delivery system
US6361796B1 (en) 1996-10-25 2002-03-26 Shire Laboratories, Inc. Soluble form osmotic dose delivery system
US6919373B1 (en) 1996-11-12 2005-07-19 Alza Corporation Methods and devices for providing prolonged drug therapy
ATE325606T1 (de) * 1996-11-25 2006-06-15 Alza Corp Dosisform mit ansteigender dosisfreisetzung
US6251587B1 (en) 1997-12-16 2001-06-26 Nova Molecular, Inc. Method for determining the prognosis of a patient with a neurological disease
ATE286725T1 (de) * 1998-10-01 2005-01-15 Novartis Pharma Gmbh Neue oral anzuwendende arzneizubereitungen für rivastigmine mit kontrollierter wirkstoffabgabe
IL142807A0 (en) * 1998-11-02 2002-03-10 Alza Corp Controlled delivery of active agents
DE69930952T2 (de) * 1998-11-02 2006-08-31 Alza Corp., Mountain View Verfahren und Vorrichtung zur kontrollierten Abgabe pharmazeutischer Mittel sowie Dosierungsform hierfür
WO2001000215A1 (en) * 1999-06-25 2001-01-04 Wake Forest University Compositions for treating or preventing neurodegeneration and cognitive decline
EP1233761B1 (en) * 1999-11-22 2007-03-28 ALZA Corporation Osmotic dosage form comprising first and second coats
CA2395231C (en) 1999-12-23 2006-08-15 Pfizer Products Inc. Hydrogel-driven layered drug dosage form
NZ518281A (en) * 1999-12-23 2005-01-28 Pfizer Prod Inc Controlled release drug dosage core comprising a drug-containing composition and a water-swellable composition
KR20040063975A (ko) * 2001-11-30 2004-07-15 화이자 프로덕츠 인크. 5,8,14-트리아자테트라시클로[10.3.1.0(2,11).0(4,9)]-헥사데카-2(11)3,5,7,9-펜타엔의 약학 조성물
US20030175346A1 (en) * 2002-02-01 2003-09-18 Anne Billotte Osmotic delivery system
US6753009B2 (en) 2002-03-13 2004-06-22 Mcneil-Ppc, Inc. Soft tablet containing high molecular weight polyethylene oxide
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
US6951658B1 (en) 2003-07-08 2005-10-04 Pearson Research & Development Limited Emu-based compositions for mental well-being and method of use
JP2007512338A (ja) * 2003-11-21 2007-05-17 メモリー・ファーマシューティカルズ・コーポレイション Ｌ型カルシウムチャンネルブロッカーとコリンエステラーゼ阻害剤を用いた組成物及び処置方法
US20050232990A1 (en) * 2003-12-31 2005-10-20 Garth Boehm Donepezil formulations
EP1749017A2 (en) * 2004-05-27 2007-02-07 MIGENIX Corp. Compounds and methods for cytoprotection
EA012220B1 (ru) * 2004-10-19 2009-08-28 Крка, Товарна Здравил, Д. Д., Ново Место Твёрдая фармацевтическая композиция, содержащая донепезила гидрохлорид
WO2006060186A2 (en) * 2004-11-30 2006-06-08 Bayer Pharmaceuticals Corporation Pyrazole derivatives for the treatment of dementia and related disorders
US20080171736A1 (en) * 2004-12-23 2008-07-17 Gregory Christopher W Treatment of Alzheimer's Disease and Mild Cognitive impairment using GnRH-I analogs and one or more of acetylcholinesterase inhibitors and NMDA receptor antagonists
US20090208579A1 (en) * 2004-12-27 2009-08-20 Eisai R & D Management Co., Ltd. Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
JP2008525313A (ja) * 2004-12-27 2008-07-17 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗痴呆薬の安定化方法
US20060280789A1 (en) * 2004-12-27 2006-12-14 Eisai Research Institute Sustained release formulations
US20070129402A1 (en) * 2004-12-27 2007-06-07 Eisai Research Institute Sustained release formulations
WO2006106514A2 (en) * 2005-04-06 2006-10-12 Nicast Ltd. Electrospun dosage form and method of producing the same
NZ562120A (en) * 2005-04-28 2010-07-30 Eisai R&D Man Co Ltd Composition comprising donepezil and memantine as antidementia agents
WO2007002597A2 (en) 2005-06-27 2007-01-04 Biovail Laboratories International S.R.L. Modified-release formulations of a bupropion salt
EP2258359A3 (en) * 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
EP2012757A2 (en) * 2006-04-24 2009-01-14 Pfizer Products Incorporated Asymmetric membranes for drug delivery devices
CA2655596C (en) * 2006-06-27 2011-10-25 Biovail Laboratories International Srl Multiparticulate osmotic delivery system
US20100173827A1 (en) * 2008-12-16 2010-07-08 Jerzy Alexander Georgiades Role of proline rich peptides in cellular communication mechanisms and treatment of diseases
CN101703488B (zh) * 2008-12-16 2013-02-20 北京科信必成医药科技发展有限公司 具有润滑层结构的双层渗透泵控释片及其制备方法
USD666376S1 (en) 2010-12-01 2012-09-04 Kraft Foods Global Brands Llc Lozenge
USD666377S1 (en) 2010-12-01 2012-09-04 Kraft Foods Global Brands Llc Lozenge
US20130143867A1 (en) 2011-12-02 2013-06-06 Sychroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
JP2016520653A (ja) 2013-06-05 2016-07-14 シンクロニューロン インコーポレイテッド アカンプロサート製剤、それを用いる方法、およびそれを含む合剤
CN105030714A (zh) * 2015-07-06 2015-11-11 长春中医药大学 阿尼西坦缓释片及其制备方法
GB201602145D0 (en) 2016-02-05 2016-03-23 Achieve Pharma Uk Ltd Salt
USD805726S1 (en) * 2016-03-11 2017-12-26 Mars, Incorporated Pet food
RU2616247C1 (ru) * 2016-03-28 2017-04-13 Федеральное государственное бюджетное образовательное учреждение высшего образования "Северо-Осетинский государственный университет имени Коста Левановича Хетагурова" (СОГУ) Твердая лекарственная форма, обладающая холинопозитивным действием, на основе 9-бутиламино-3,3-диметил-1,2,4-тригидроакридина
KR20220044543A (ko) * 2019-08-08 2022-04-08 에보니크 오퍼레이션즈 게엠베하 고체 투여 형태를 제조하는 방법 및 윤활제

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2799241A (en) * 1949-01-21 1957-07-16 Wisconsin Alumni Res Found Means for applying coatings to tablets or the like
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
GB1478759A (en) * 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4077407A (en) * 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4063064A (en) * 1976-02-23 1977-12-13 Coherent Radiation Apparatus for tracking moving workpiece by a laser beam
US4327725A (en) * 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4765989A (en) * 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US4612008A (en) * 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US4783337A (en) * 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US4857330A (en) * 1986-04-17 1989-08-15 Alza Corporation Chlorpheniramine therapy
US4816456A (en) * 1986-10-01 1989-03-28 Summers William K Administration of monoamine acridines in cholinergic neuronal deficit states
AU1589492A (en) * 1991-03-01 1992-10-06 Warner-Lambert Company Starch-based controlled release compositions
US5518730A (en) * 1992-06-03 1996-05-21 Fuisz Technologies Ltd. Biodegradable controlled release flash flow melt-spun delivery system
JPH09500645A (ja) * 1993-07-22 1997-01-21 ワーナー−ランバート・コンパニー 制御放出タクリン薬物送達システムおよびその製造方法
US5698224A (en) * 1994-06-27 1997-12-16 Alza Corporation Tacrine therapy
EP0788793A1 (en) * 1996-02-01 1997-08-13 Takeda Chemical Industries, Ltd. Idebenone for the treatment of dementia

Also Published As

Publication number Publication date
NO965539L (no) 1997-02-25
WO1996000065A1 (en) 1996-01-04
AU2864495A (en) 1996-01-19
AU685297B2 (en) 1998-01-15
JPH10507440A (ja) 1998-07-21
US6036973A (en) 2000-03-14
EP0768880A1 (en) 1997-04-23
KR970703768A (ko) 1997-08-09
FI965202A0 (fi) 1996-12-23
NZ288951A (en) 1997-04-24
US5698224A (en) 1997-12-16
NO965539D0 (no) 1996-12-23
FI965202A (fi) 1996-12-23
CA2187332A1 (en) 1996-01-04

Similar Documents

Publication Publication Date Title
MX9700081A (es) Composiciones farmaceuticas de tacrina.
GR1000932B (el) Δοσολογικη μορφη για την χορηγηση υπογλυκαιμικης γλιπιζιδης απο το στομα.
ZA913282B (en) Dosage form
AU6060896A (en) Oral 1alpha-hydroxyprevitamin D
EG19642A (en) A process for the preparation of oral composition for the treatment of inflammatory bowel diseases
GEP20002142B (en) Method for Treatment and Prevention of TNF Mediated Diseases
IL91656A0 (en) Pharmaceutical composition containing a benzodiazepine derivative
IL123889A0 (en) Pharmaceutical angiostatic dipeptide compositions and methods of use thereof
YU49026B (sh) UPOTREBA 17 Гџ -(N-TERC-BUTILKARBAMOIL)-4-AZA-5-ALFA-ANDROST-1-3-ON ZA PROIZVODNJU LEKA ZA TRETIRANJE ANDROGENE ALOPECIJE
IL103303A (en) Pharmaceutical compositions containing ibuprofen and codeine for relief of chronic pain
GR3034186T3 (en) 3,4-diarylchromans for treatment of dermatitis
ES2026304A6 (es) Procedimiento de fabricacion de una forma de dosificacion de nicardipina.
HK1034446A1 (en) Therapeutic agents.
MY124465A (en) Reduction of infarct volume using citicoline
NO974486L (no) Lavdoserte "Ridogrel"-formuleringer samt anvendelse derav ved behandling av tarmbetennelse
PH31582A (en) Glycoslated cytokins.
NZ303993A (en) Pharmaceutical compositions containing aminotetralin derivatives for treating cardiac disorders
DE3369327D1 (en) Pharmaceutical compounds, preparation, use and intermediates therefor and their preparation
BG102266A (en) Method for the preparation of solid batched forms having very low doses of the medicamentous form
AU4918900A (en) Interferon-beta use in the treatment of ewing's family of tumors
RU99112967A (ru) Способ лечения и профилактики дизентерии свиней
UA15281A (uk) Спосіб лікуваhhя хроhічhої ішемічhої хвороби серця
UA30251A (uk) Спосіб лікування гіпертонії сфінктера одді у хворих на хронічний безкам'яний холецистит при поєднанні з підвищенням тонусу симпатичної нервової системи
MY110769A (en) Controlled release oxycodone compositions.
AU1470697A (en) Method and compositions for noninvasive dose to effect administration of lipophilic drugs